Comparative Pharmacology
Head-to-head clinical analysis: DYANAVEL XR 5 versus LISDEXAMFETAMINE DIMESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYANAVEL XR 5 versus LISDEXAMFETAMINE DIMESYLATE.
DYANAVEL XR 5 vs LISDEXAMFETAMINE DIMESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CNS stimulant; blocks reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their synaptic concentrations.
Lisdexamfetamine is a prodrug of dextroamphetamine, which blocks the reuptake of norepinephrine and dopamine from the synaptic cleft and increases their release into the extraneuronal space.
20 mg orally once daily in the morning; may increase by 10 mg weekly based on response; maximum 60 mg/day.
30–70 mg orally once daily in the morning.
None Documented
None Documented
Terminal elimination half-life for d-amphetamine is 10-13 hours; for l-amphetamine, 13-16 hours. Clinical context: Twice-daily dosing may be required for sustained effect.
Terminal elimination half-life of lisdexamfetamine is approximately 1 hour (prodrug conversion), while dextroamphetamine (active moiety) has a half-life of 10-12 hours in adults. In children, half-life is slightly shorter (9-11 hours). Clinically, once-daily dosing provides symptom control for ADHD.
Renal: ~90% as unchanged amphetamine and metabolites. Fecal: minimal (<5%).
Primarily renal: approximately 95% of the dose is excreted in urine, with about 70% as intact lisdexamfetamine, 20% as dextroamphetamine and its metabolites (hippuric acid, benzoic acid), and minimal biliary/fecal elimination (<5%).
Category C
Category C
CNS Stimulant
CNS Stimulant